source
- Moderna and Merck vaccine plus Keytruda cuts melanoma relapse risk by 42% in late-stage trialA late-stage adjuvant study of Moderna’s experimental melanoma vaccine, intismeran autogene, combined with Merck’s Keytruda showed a 42% reduction in the risk of relapse or death compared with Keyt…
- Celltrion licenses Kaigene's preclinical antibody KG013 in deal worth up to $580.5 millionCelltrion, a South Korean biotech, has entered into a licensing agreement with Maryland-based Kaigene for a preclinical monoclonal antibody known as KG013. KG013 is designed to block the prolifera…